Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma

CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we develope...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuejiao Huang, Yiming Gong, Xiang Liu, Huaying Ruan, Jinhua Lu, Hosein Kouros-Mehr, Hong Liu, Han Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
CAR T-cell therapy
transformed follicular lymphoma
CD20
CD30
bispecific CAR T
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567149/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567149/full

Similar Items